FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)
John Souglakos(University of Crete), Vassilis Georgoulias(Metropolitan College)
Cited by 402
Related Papers
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
|Science Translational Medicine|2011|670
IGF-I and IGF-II in relation to colorectal cancer
|International Journal of Cancer|1999|193
Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group
|European Journal of Cancer|2018|34
Federated Deep Learning Enables Cancer Subtyping by Proteomics
|Cancer Discovery|2025|9